Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/140678
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Boada, Mercè | - |
dc.contributor.author | Anaya, Fernando | - |
dc.contributor.author | Ortiz, Pilar | - |
dc.contributor.author | Olazarán, Javier | - |
dc.contributor.author | Shua-Haim, Joshua R. | - |
dc.contributor.author | Obisesan, Thomas O. | - |
dc.contributor.author | Hernández, Isabel | - |
dc.contributor.author | Muñoz, Joan | - |
dc.contributor.author | Buendia, Mar | - |
dc.contributor.author | Alegret i Llorens, Montse | - |
dc.contributor.author | Lafuente, Asunción | - |
dc.contributor.author | Tárraga, Lluís | - |
dc.contributor.author | Núñez Doménech, Laura | - |
dc.contributor.author | Torres Hurtado, Mirea | - |
dc.contributor.author | Grífols, Joan Ramon | - |
dc.contributor.author | Ferrer, Isidro (Ferrer Abizanda) | - |
dc.contributor.author | Lopez, Oscar L. | - |
dc.contributor.author | Páez, Antonio | - |
dc.date.accessioned | 2019-09-20T14:35:24Z | - |
dc.date.available | 2019-09-20T14:35:24Z | - |
dc.date.issued | 2017-01 | - |
dc.identifier.issn | 1387-2877 | - |
dc.identifier.uri | http://hdl.handle.net/2445/140678 | - |
dc.description.abstract | Background: studies conducted in animal models and humans suggest the presence of a dynamic equilibrium of amyloid-β (Aβ) peptide between cerebrospinal fluid (CSF) and plasma compartments. Objective: to determine whether plasma exchange (PE) with albumin replacement was able to modify Aβ concentrations in CSF and plasma as well as to improve cognition in patients with mild-moderate Alzheimer's disease (AD). Methods: in a multicenter, randomized, patient- and rater-blind, controlled, parallel-group, phase II study, 42 AD patients were assigned (1 : 1) to PE treatment or control (sham) groups. Treated patients received a maximum of 18 PE with 5% albumin (Albutein®, Grifols) with three different schedules: two PE/weekly (three weeks), one PE/weekly (six weeks), and one PE/bi- weekly (12 weeks), plus a six-month follow-up period. Plasma and CSF Aβ1-40 and Aβ1-42 levels, as well as cognitive, functional, and behavioral measures were determined. Results: CSF Aβ1-42 levels after the last PE compared to baseline were marginally higher in PE-treated group versus controls (adjusted means of variation: 75.3 versus -45.5 pg/mL; 95% CI: -19.8, 170.5 versus 135.1, 44.2; p = 0.072). Plasma Aβ1-42 levels were lower in the PE-treated group after each treatment period (p < 0.05). Plasma Aβ1-40 levels showed a saw-tooth pattern variation associated with PE. PE-treated patients scored better in the Boston Naming Test and Semantic Verbal Fluency (p < 0.05) throughout the study. Neuropsychiatric Inventory scores were higher in controls during the PE phase (p < 0.05). Conclusion: PE with human albumin modified CSF and plasma Aβ1-42 levels. Patients treated with PE showed improvement in memory and language functions, which persisted after PE was discontinued. | - |
dc.format.extent | 15 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | IOS Press | - |
dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.3233/JAD-160565 | - |
dc.relation.ispartof | Journal of Alzheimer's Disease, 2017, vol. 56, num. 1, p. 129-143 | - |
dc.relation.uri | https://doi.org/10.3233/JAD-160565 | - |
dc.rights | (c) Boada, Mercè et al., 2017 | - |
dc.source | Articles publicats en revistes (Patologia i Terapèutica Experimental) | - |
dc.subject.classification | Albúmines | - |
dc.subject.classification | Ús terapèutic | - |
dc.subject.classification | Pèptids | - |
dc.subject.classification | Sang | - |
dc.subject.classification | Líquid cefalorraquidi | - |
dc.subject.classification | Trastorns de la cognició | - |
dc.subject.other | Albumins | - |
dc.subject.other | Therapeutic use | - |
dc.subject.other | Peptides | - |
dc.subject.other | Blood | - |
dc.subject.other | Cerebrospinal fluid | - |
dc.subject.other | Cognition disorders | - |
dc.title | Efficacy and safety of plasma exchange with 5% albumin to modify cerebrospinal fluid and plasma amyloid-β concentrations and cognition outcomes in Alzheimer's disease patients: a multicenter, randomized, controlled clinical trial | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.identifier.idgrec | 690149 | - |
dc.date.updated | 2019-09-20T14:35:24Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 27911295 | - |
Appears in Collections: | Articles publicats en revistes (Patologia i Terapèutica Experimental) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
690149.pdf | 530.3 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.